PCM
AQST icon

Prelude Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Prelude Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,054
Closed -$212K – 1241
2026
Q1 		$212K Buy
51,054
+30,485
+148% +$124K 0.02% 883
2025
Q4 		$133K Sell
20,569
-17,904
-47% -$112K 0.01% 1145
2025
Q3 		$215K Sell
38,473
-26,229
-41% -$113K 0.02% 909
2025
Q2 		$214K Buy
64,702
+16,361
+34% +$46.9K 0.02% 786
2025
Q1 		$140K Buy
48,341
+36,409
+305% +$110K 0.01% 996
2024
Q4 		$42.5K Sell
11,932
-4,576
-28% -$21.1K ﹤0.01% 1153
2024
Q3 		$82.2K Sell
16,508
-71,882
-81% -$280K 0.01% 1177
2024
Q2 		$230K Buy
88,390
+63,594
+256% +$212K 0.02% 925
2024
Q1 		$106K Buy
+24,796
New +$82.5K 0.01% 1196
2019
Q1 		– Sell
-201
Closed -$1K – 1746
2018
Q4 		$1K Buy
+201
New +$2.54K ﹤0.01% 1706

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Prelude Capital Management's AQST Position: Q2 2026 in Review

Prelude Capital Management sold out of Aquestive Therapeutics (AQST) in Q2 2026, closing a stake of 51,054 shares — an estimated $212K sold.

Prelude Capital Management first reported a position in AQST in Q4 2018 and held it in 10 quarters. The position peaked at $230K in Q2 2024. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Prelude Capital Management reported no remaining Aquestive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 51,054 Aquestive Therapeutics shares in Q2 2026, an estimated $212K.
  • Prelude Capital Management first reported a position in Aquestive Therapeutics in Q4 2018 and held it in 10 quarters.
  • Prelude Capital Management's Aquestive Therapeutics position peaked at $230K in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.